Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Certolizumab may reduce uveitis flares, axSpA disease activity

Key clinical point: Certolizumab pegol reduces recurrent acute anterior uveitis flares, improves disease activity in patients with axial spondyloarthritis, and provides more benefit with earlier treatment.

Major finding: Acute anterior uveitis flares decreased by 87% during versus prior to certolizumab pegol treatment.

Study details: The open-label, phase 4 C-VIEW study of 85 patients, and a post hoc analysis of data from 317 patients in the C-axSpAnd study.

Disclosures: The C-VIEW and C-axSpAnd studies were funded by UCB. Dr. van der Horst-Bruinsma reported receiving honoraria, consulting fees, and/or research grants from UCB as well as from AbbVie, Bristol-Myers Squibb, Merck, Novartis, and Pfizer. Dr. Kay reported receiving grant/research support from Gilead, Pfizer, and UCB and consulting fees from AbbVie, Alvotech, Boehringer Ingelheim, Celltrion, Merck, Novartis, Samsung Bioepis, Sandoz, and UCB.


van der Horst-Bruinsma I et al. Arthritis Rheumatol. 2019;71(suppl 10), Abstract 935; Kay J et al. Arthritis Rheumatol. 2019;71(suppl 10), Abstract 936.